



Pergamon

A new synthesis of the 2,2,3,5,6,6-substituted tetrahydropyran aplysiapyranoid A and its 5-epimer

Jens Hartung* and Marco Greb

Institut für Organische Chemie, Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany

Received 31 March 2003; revised 12 May 2003; accepted 12 June 2003

Abstract—The vanadium(V)-catalyzed oxidation of bromide in the presence of methyl (*E*)-2-(1-hydroxy-1-methylethyl)-5-phenyl-4-hexenoate furnished 5,6-*trans*-5-bromo-6-phenyl-2,2,6-trimethyl-3-methyloxycarbonyltetrahydropyran, which was converted into the marine natural product aplysiapyranoid A and its 5-epimer, via a short sequence of decarboxylative bromination and transition metal-based procedures for transforming a phenyl into a chlorovinyl substituent.

© 2003 Elsevier Ltd. All rights reserved.

Aplysiapyranoids A–D are monoterpene-derived secondary metabolites, which have been isolated from the midgut gland of the sea hare *Aplysia kurodai*.^{1,2} Due to their cytotoxic profile towards several human tumor cell lines, in association with their restricted availability from natural sources, aplysiapyranoids have become attractive targets in organic synthesis.^{3–5} In order to provide adequate quantities of these compounds for succeeding biological experiments it was desired to develop a new synthesis, which was based on a catalytic procedure for constructing the bromofunctionalized tetrahydropyran nucleus from a suitable bishomoallylic alcohol. Further, it was considered useful to design an approach that would allow an application of polar and free radical reactions for subsequent functional group interconversions in order to establish a straightforward access to a wider range of analogues of heterocycle **1** in

future investigations. In regard of these prerequisites, styrene derivative **2** was chosen as substrate for a new synthesis of aplysiapyranoid A (**1**) and its 5-epimer *epi-1* (Fig. 1).^{†,‡} A phenyl substituent is known to exhibit a comparatively strong polar effect in electrophilic bromination reactions of olefins and thus was thought to significantly favor a 6-*endo*-selective ring closure reaction in the initial step.⁶ Introduction of the second bromo substituent into the heterocyclic core was expected to be feasible via a decarboxylative free radical bromination.⁷ A subsequent oxidative degradation of the phenyl into a carbonyl functionality⁸ then would provide an appropriate starting point for constructing the (*E*)-configured chlorovinyl substituent of target compounds **1** and *epi-1*.




Figure 1. Concept for the construction of aplysiapyranoid A (+)-(**1**).

* Corresponding author.


[†] Satisfactory analytical data were obtained for all new compounds prepared in this study. The present communication reports on a proof of concept. Therefore it has been restricted to the synthesis of racemic aplysiapyranoid A (**1**) and *epi-1*.

[‡] Methyl (*E*)-2-(1-hydroxy-1-methylethyl)-5-phenyl-4-hexenoate (**2**) was prepared by esterification of 4-benzoyl butyric acid (CH₃OH, CHCl₃, TsOH, 61°C), selective methylation (CH₃MgI, Et₂O, 20°C), treatment of this crude product with TsOH in a mixture of C₆H₆ and CH₃OH (oil bath: 95°C), and subsequent α -alkylation (LDA, THF, –78°C, then acetone): ¹H NMR (CDCl₃, 250 MHz): δ = 1.29 (2 s, 6H), 2.03 (s, 3H), 2.30–2.44 (br. s, 1H), 2.43–2.77 (m, 2H), 2.55 (m, 1H), 3.68 (s, 3H), 5.67 (tq, *J* = 6.7 Hz, *J* = 1.5 Hz, 1H), 7.21–7.36 (m, 5H). ¹³C NMR (CDCl₃, 63 MHz): δ = 16.0, 26.8, 27.0, 29.2, 51.6, 55.7, 71.0, 124.8, 125.7, 126.8, 128.2, 137.0, 143.8, 176.1. C₁₆H₂₂O₃ (262.34): calcd C, 73.25; H, 8.45; found: C, 73.72; H, 8.33.

Thus, methyl (*E*)-2-(1-hydroxy-1-methylethyl)-5-phenyl-4-hexenoate (**2**)⁸ was treated on a 15 g scale with *tert*-butyl hydroperoxide (TBHP), pyridinium hydrobromide and 5 mol% of catalyst VOL(OEt)(EtOH) [L = *N*-(2-hydroxyphenyl)salicylideneimine dianion]^{9,10} to furnish 43% of 6-*endo*-bromocyclized product **3** (3,5-*cis*:3,5-*trans* = 80:20) besides 15% of tetrahydrofuran **4** (*cis*:*trans* = 34:66, Scheme 1).¹¹ Substituents at C5 and C6 in both diastereomers of **3** exhibited relative *trans*-configuration. Formation of 5-(1-phenyl-1-hydroxy-1-ethyl)-substituted tetrahydrofurans or the corresponding tetrahydropyrans as side products, which might have originated from a competing direct vanadium(V)-catalyzed oxygenation of substrate **2**, was not observed.¹¹ It is worth mentioning that treatment of a solution of alkenol **2** in CH₂Cl₂ (20°C or 40°C) with the standard reagent for conducting 6-*endo*-selective ring closure reactions, i.e. 2,4,4,6-tetrabromocyclohexadienone,^{3–5,12,13} provided 5,6-*trans*-configured tetrahydropyran **3** in yields that remained below 20%. Surprisingly, the diastereoselectivity for a likewise obtained product **3** with regard to substitution at C3 and C5 was reversed (3,5-*cis*:3,5-*trans* = 26:74, not shown in Scheme 1).


Saponification of methyl ester **3** using LiOH in aqueous dimethoxyethane (DME) furnished upon neutralization the corresponding carboxylic acid (3,5-*cis*:3,5-*trans* = 80:20, 93%, not shown in Scheme 2). Treatment of the latter compound with *N*-hydroxypyridine-2(1*H*)thione (PTOH) and diisopropylcarbodiimide (DIC) provided mixed anhydride **5** (Scheme 2).⁷ Photolysis of alkyl radical precursor **5** in the presence of BrCCl₃ led to the formation of dibromide **6** (3,5-*cis*:3,5-*trans* = 50:50, 52% starting from the carboxylic acid derivative of **3**).

For completion of both syntheses, separated dibromides 3,5-*trans*-**6** and 3,5-*cis*-**6** were treated with the reagent combination of RuCl₃ and NaIO₄ in order to transform in both instances the phenyl substituent into a carboxyl group (Scheme 3). Since this procedure had originally been developed for preparing carboxylic acids from less functionalized aromatic hydrocarbons,⁸ we were pleased to notice that it was also suitable for a




Scheme 1. Application of the vanadium(V)-catalyzed oxidation of bromide in the 6-*endo*-selective bromocyclization of styrene-derived alcohol **2**. *Reagents and conditions:* (a) TBHP (1.1 equiv.), C₃H₅N·HBr (1.5 equiv.), VOL(OEt)(EtOH) [5 mol%, L = *N*-(2-hydroxyphenyl)salicylideneimine dianion]^{9,10}, CH₃CN, 20°C.

chemoselective transformation of both diastereomers of **6**. However, it should be added that the conversion of starting material **6** ceased at some point. It was not possible to resume its oxidation by adding further RuCl₃ or supplementary NaIO₄ to the reaction mixture. Since separation of likewise prepared carboxylic acids from unreacted substrate **6** at that stage of the synthesis was tedious and associated with loss of substantial amounts of oxidation product, the crude material was treated with MeOH and DIC to provide esters **7** and *epi*-**7**, which were purified by chromatography (Scheme 3). Reduction of the ester functionality in **7** and *epi*-**7** using DIBAH in hexanes/CH₂Cl₂ afforded the corresponding aldehydes. Treatment of these products with CrCl₂ and CHCl₃ furnished target compounds **1** and



Scheme 2. Formation of 3,5-dibromo-2,2,6,6-substituted tetrahydropyran **6** from heterocyclic ester **3**. *Reagents and conditions:* (a) LiOH, DME, H₂O, 20°C (93%); (b) PTOH, DIC, CH₂Cl₂; (c) BrCCl₃, C₆H₆, *hν*, 20°C (52% for steps b and c).



Scheme 3. Completion of the synthesis of aplysiapyranoid **A** (**1**) and *epi*-**1**, both as racemates. *Reagents and conditions:* (a) RuCl₃, NaIO₄, CCl₄, CH₃CN, H₂O, 20°C; (b) CH₃OH, DIC, CH₂Cl₂ (36% for 3,5-*trans*-**6**→**7**, 46% for 3,5-*cis*-**6**→*epi*-**7**); (c) DIBAH in hexanes, CH₂Cl₂, -78°C; (d) CrCl₂, CHCl₃, THF, 61°C (33% for **7**→**1**, 22% for *epi*-**7**→*epi*-**1**).

epi-**1**.^{§,14} The sample of aplysiapyranoid A (**1**) was contaminated with a minor amount of its dechlorinated derivative (4%) and 10% of starting aldehyde, which could be separated from **1** by column chromatography. The final step from the synthesis of *epi*-**1** was not associated with similar complications.

The observation that only moderate yields were attainable from optimized synthetic procedures, which are outlined in Scheme 3, was unexpected and deserves a comment. This fact had been noted for the chloroethenylation step in the synthesis of (+)-**1** in an earlier report.³ According to our experience, this issue has to be associated with the significant steric crowding in 2,2,3,5,6,6-substituted tetrahydropyrans that sometimes rendered seemingly elementary reactions into troublesome processes.

In summary, we have devised a new synthesis of aplysiapyranoid A (**1**) and its isomer *epi*-**1**, both as racemates. The selected strategy supplements the existing approach.³ It offers potential for future syntheses of new aplysiapyranoid derivatives, since it takes profit from a transition metal-catalyzed oxidation in the bromine cyclization step and enables the preparation of related compounds under mild and neutral conditions using radical-based transformations.

Acknowledgements

Generous financial support was provided by the Deutsche Forschungsgemeinschaft (Grants, Ha 1705/6-1 and 8-1) and the Fonds der Chemischen Industrie. Further, we express our gratitude to Mrs. Katharina

Klüh, undergraduate research participant, for technical assistance.

References

1. Kusumi, T.; Uchida, H.; Inouye, Y.; Ishitsuka, M.; Yamamoto, H.; Kakisawa, H. *J. Org. Chem.* **1987**, *52*, 4597–4600.
2. Inoue, Y.; Uchida, H.; Kusumi, T.; Kakisawa, H. *J. Chem. Soc., Chem. Commun.* **1987**, 346–347.
3. Jung, M. E.; D'Amico, D. C.; Lew, W. *Tetrahedron Lett.* **1993**, *34*, 923–926.
4. Jung, M. E.; Fahr, B. T.; D'Amico, D. C. *J. Org. Chem.* **1998**, *63*, 2982–2987.
5. Jung, M. E.; Lew, W. *J. Org. Chem.* **1991**, *56*, 1348–1349.
6. For examples, see: Conte, V.; Di Furia, F.; Moro, S. *Tetrahedron Lett.* **1996**, *47*, 8609–8612.
7. Motherwell, W. B.; Imboden, C. In *Radicals in Organic Synthesis*; Renaud, P.; Sibi, M. P., Eds.; Wiley-VCH: Weinheim, 2001; Vol. 1, pp. 109–134.
8. Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. *J. Org. Chem.* **1981**, *46*, 3936–3938.
9. Mimoun, H.; Mignard, M.; Brechot, P.; Saussine, L. *J. Am. Chem. Soc.* **1986**, *108*, 3711–3718.
10. Hartung, J.; Greb, M. *J. Organomet. Chem.* **2002**, *661*, 67–84.
11. The procedure has been applied in: Hartung, J.; Kunz, P.; Laug, S.; Schmidt, P. *Synlett* **2003**, 51–54.
12. Corey, E. J.; Ha, D.-C. *Tetrahedron Lett.* **1988**, *29*, 3171–3174.
13. González, A. G.; Martín, J. D.; Pérez, C.; Ramírez, M. A.; Ravelo, F. *Tetrahedron Lett.* **1981**, *22*, 5071–5072.
14. Takai, K.; Nitta, K.; Utimoto, K. *J. Am. Chem. Soc.* **1986**, *108*, 7408–7410.

§ **1**: ¹H NMR (CDCl₃, 400 MHz): δ=1.38 (s, 3H), 1.43 (s, 6H), 2.61–2.68 (m, 2H), 4.39 (dd, *J*=7.8, 5.0 Hz, 1H, CHBr), 4.47 (dd, *J*=6.2, 4.0 Hz, 1H, CHBr), 6.14 (d, *J*=13.8 Hz, 1H), 6.18 (d, *J*=13.8 Hz, 1H). ¹³C NMR (CDCl₃, 101 MHz): δ=27.3, 28.7, 29.0, 37.3, 54.6, 55.1, 75.8, 76.0, 118.4, 138.4. *epi*-**1**: ¹H NMR (CDCl₃, 400 MHz): δ=1.36 (s, 3H), 1.47 (s, 3H), 1.53 (s, 3H), 2.59–2.70 (m, 2H), 3.87 (m, 2H, 2 CHBr), 6.09 (d, *J*=13.1 Hz, 1H), 6.29 (d, *J*=13.1 Hz, 1H). ¹³C NMR (CDCl₃, 101 MHz): δ=22.1, 23.3, 30.4, 38.3, 52.8, 53.9, 76.8, 77.1, 119.9, 137.8.